That is expected to increase to $6.3 billion in 2014, for a compound annual growth rate (CAGR) of 2.7%.
The market is broken down into vaccines, therapeutics, and diagnostic products. The vaccines segment has the largest share of the market, worth an estimated $3.2 billion in 2009. This segment is expected to grow at a CAGR of 5.6% to reach nearly $4.2 billion in 2014.
The therapeutics segment has the second-largest share of the market with $2.1 billion in 2009. But that segment is expected to decrease at a CAGR of -2.4%, falling to $1.9 billion in 2014.
An aging population is a significant driver in the growth of the market, boosting sales for products directed to preventive measures while the international market continues to show promise in vaccination, treatment, and diagnosis.
The influenza market consists of products to prevent, treat, and diagnose influenza viruses during both seasonal and pandemic episodes. Also included in the market is the stockpiling efforts and spending on new vaccine/therapeutic contracts.
As many as 500,000 people die of influenza annually and, with the threat of a pandemic, government agencies and disease-prevention organizations are devoted to gaining control of the situation. Many companies have been asked to assist with the problem and others are furthering their position with backing from government agencies. The next five years will continue to display support and funding for many research and development programs, product development and pandemic prevention and/or control by worldwide governments, organizations, and health professionals.
The study includes information about products available, products in development, issues and trends influencing the market, and competitive analysis of top providers. A special emphasis on U.S. and European markets is discussed. An electronic PDF of this report is available for $4,850. BCC Research is a publisher of market research reports and technical publications.
The market is broken down into vaccines, therapeutics, and diagnostic products. The vaccines segment has the largest share of the market, worth an estimated $3.2 billion in 2009. This segment is expected to grow at a CAGR of 5.6% to reach nearly $4.2 billion in 2014.
The therapeutics segment has the second-largest share of the market with $2.1 billion in 2009. But that segment is expected to decrease at a CAGR of -2.4%, falling to $1.9 billion in 2014.
An aging population is a significant driver in the growth of the market, boosting sales for products directed to preventive measures while the international market continues to show promise in vaccination, treatment, and diagnosis.
The influenza market consists of products to prevent, treat, and diagnose influenza viruses during both seasonal and pandemic episodes. Also included in the market is the stockpiling efforts and spending on new vaccine/therapeutic contracts.
As many as 500,000 people die of influenza annually and, with the threat of a pandemic, government agencies and disease-prevention organizations are devoted to gaining control of the situation. Many companies have been asked to assist with the problem and others are furthering their position with backing from government agencies. The next five years will continue to display support and funding for many research and development programs, product development and pandemic prevention and/or control by worldwide governments, organizations, and health professionals.
The study includes information about products available, products in development, issues and trends influencing the market, and competitive analysis of top providers. A special emphasis on U.S. and European markets is discussed. An electronic PDF of this report is available for $4,850. BCC Research is a publisher of market research reports and technical publications.
